GlassScriptPhysician profile
Peter Zloty
NPI 1467490086
$4,523.05
in general payments reported to CMS, 2019-2025
22 companies · $818 in 2025
The $818 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $691 · 2020: $346 · 2021: $808 · 2022: $534 · 2023: $863 · 2024: $463 · 2025: $818.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,126 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,126.47 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $1,308.45 | 2019-2025 | Tecnis Iol, Amo Phaco Needle, Tecnis Iol |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $683.48 | 2019-2021 | |
| Alcon Vision LLC | $571.53 | 2019-2025 | Hydrus Microstent, Clareon, Eysuvis |
| Glaukos Corporation | $522.27 | 2021-2025 | Idosetr, Idose, Istent Trabecular Micro-Bypass Stent System |
| Bausch & Lomb Americas INC. | $295.87 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Sun Pharmaceutical Industries INC. | $180.76 | 2019-2022 | |
| Allergan, INC. | $161.91 | 2020-2022 | |
| Dompe US, INC. | $144.26 | 2022-2025 | Oxervate |
| Oyster Point Pharma, INC. | $131.88 | 2023 | Tyrvaya |
| Abbvie INC. | $111.17 | 2022-2024 | |
| Lkc Technologies, INC. | $101.14 | 2025 | |
| Sight Sciences, INC. | $64.58 | 2024 | Omni Surgical System |
| Rayner Intraocular Lenses Limited | $49.72 | 2023 | Rayone Aspheric, Rayone Emv, Rayone Spheric |
| Novartis Pharmaceuticals Corporation | $43.32 | 2019-2021 | |
| New World Medical,INC. | $39.29 | 2023-2025 | Clearpath, Streamline, Via360 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $18.76 | 2025 | |
| Amgen INC. | $17.53 | 2025 | Tepezza |
| Aerie Pharmaceuticals, INC. | $16.98 | 2019 | |
| Eyevance Pharmaceuticals LLC | $16.61 | 2021 | |
| Rxsight INC | $15.47 | 2022 | |
| Ocular Therapeutix, INC. | $14.75 | 2021 | |
| Kala Pharmaceuticals, INC. | $13.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Zloty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.